Following a roller-coaster few months politically, it is good to return to an attractively priced, well-managed investment which has progressed its business model over the last quarter. Ergomed’s recent acquisition adds a further high growth revenue stream to its portfolio and, along with the Asarina co-development, adds 34p to our valuation per share which remains well above current levels with a range of 163-301p.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Adding earnings. Adding future upside
- Published:
13 Dec 2016 -
Author:
Elizabeth Klein -
Pages:
6
Following a roller-coaster few months politically, it is good to return to an attractively priced, well-managed investment which has progressed its business model over the last quarter. Ergomed’s recent acquisition adds a further high growth revenue stream to its portfolio and, along with the Asarina co-development, adds 34p to our valuation per share which remains well above current levels with a range of 163-301p.